Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell L...(survival ratesaccording to histological ...),Health

Date:5/28/2008

survival rates according to histological analysis, it was found that patients with adenocarcinoma achieved 12.6 months of overall median survival when treated with the pemetrexed regimen compared to 10.9 months for those treated with the gemcitabine regimen. Patients with large cell carcinoma who were treated with the pemetrexed regimen achieved 10.4 months of overall median survival versus 6.7 months for those treated with the gemcitabine regimen. Both findings are statistically significant.

Comparatively, patients with squamous cell histology were found to have a more favorable rate of survival when treated with the gemcitabine regimen, achieving 10.8 months of median survival, compared to the 9.4 months for those treated with the pemetrexed regimen. This finding also was statistically significant.

The Phase III, randomized study compared the overall survival between pemetrexed+cisplatin versus gemcitabine+cisplatin in 1,725 chemonaive patients with stage IIIB or IV NSCLC who also exhibited a performance status of 0-1. Patients on the pemetrexed arm (n = 862) were treated with pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) on day one every three weeks for up to six cycles. Patients on the gemcitabine arm (n = 863) were treated with cisplatin (75 mg/m2) on day one and gemcitabine (1250 mg/m2) on days one and eight every three weeks for up to six cycles.

Hematologic grade 3/4 drug-related toxicities - neutropenia, anemia and thrombocytopenia - were significantly lower for patients on the pemetrexed arm (p less than or equal to 0.001). Drug-related grade 3/4 febrile neutropenia (p = 0.002) and alopecia (all grades; p < 0.001) were also significantly less on the pemetrexed arm. However, drug-related grade 3/4 nausea (p = 0.004) was more common in patients treated with pemetrexed. Safety data by histology was generally consistent with the overall safety results.

"In research, we're always looking for a new door to open - a different way of
'/>"/>

SOURCE Eli Lilly and Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine news :

1. Global study reveals differences in standard of care for osteoporosis across the world
2. New study shows positive role physical therapists play in lymphedema diagnois and treatment
3. RTOG Study Likely Treatment Option for Brain Tumor Patients like Sen. Kennedy
4. New CDC Study Shows Smoke-Free Laws Spreading Across U.S. and Should Spur Remaining States to Take Action
5. Experimental agent blocks prostate cancer in animal study
6. Study finds unique HIV vaccine formula elicits strong immune responses
7. First of its kind study compares high school knee injuries by sport and gender
8. UNC study firms up promise of potential new cervical cancer screening tool
9. Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50
10. Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon
11. Israeli study finds obstructive sleep apnea is health factor from day 1